Dr. Dreicer on Future Treatment Approaches in Prostate Cancer

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses the progress he would like to see accomplished in the field of metastatic castration-resistant prostate cancer.

It would be a huge step in the field, Dreicer explains, to have AR-V7 assays that are validated and commercially available. Additionally, he hopes to see more prospective data to validate what was previously demonstrated by researchers of Johns Hopkins Medicine with the AR-V7 Prostate Cancer Assay. Although such data were interesting, they were small numbers, and prospective validation from other centers would be useful before all physicians incorporate it into their daily practice.

Dreicer also hopes that, over the next year, the community is able to move some new compounds down the pipeline that may have abilities to overcome some resistance pathways. Researchers are looking to use the androgen receptor-pathway downstream.